ClinicalTrials.gg
RecruitingNCT05597345Updated Feb 10, 2025

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

A Phase 2 interventional study of Selinexor in Smoldering Multiple Myeloma, sponsored by University of Rochester. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by University of Rochester · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Smoldering Multiple Myeloma with a site in United States — 20 open to participants now, 34 under way, 4 of them phase 3. Smoldering Multiple Myeloma · United States.

Planned enrollment
44th of 56
15 · median 30
Started
2023
with 5 others
Phase 2
30 of 71
4 open now
Primary completion
2024-10
later than 6 of 33 live
Registered
60th of 71
by date
Lead sponsor
3 of 71
University of Rochester

Among the 71 studies in Smoldering Multiple Myeloma with a site in United States, this one is the 44th largest by planned enrollment of the 56 interventional ones that give a count, is one of 6 that started in 2023, is one of 30 in phase 2, reaches primary completion later than 6 of the 33 other live ones, and was the 60th registered.

Smoldering Multiple Myeloma

101 studies on the registry are indexed under Smoldering Multiple Myeloma; 34 are open to participants now.

Browse Smoldering Multiple Myeloma studies →

Open to participants now

20 of the 71 studies in Smoldering Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Smoldering Multiple Myeloma studies recruiting now, 27 (90%) set no upper age limit and 1 (3%) stops at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Smoldering Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical trials investigating interventions to delay progression to multiple myeloma and prevent or delay disease related outcomes. A subset of patients with intermediate or high risk smoldering multiple myeloma have a much higher risk of progressive to multiple myeloma, while the low risk smoldering myeloma patient population has a much lower risk. This is a clinical trial investigating the use of low-dose selinexor in patients with intermediate to high-risk smoldering multiple myeloma. The investigators hypothesize that the use of selinexor in intermediate to high risk smoldering myeloma patients will help to delay progression of disease to symptomatic multiple myeloma.

Read the detailed description

Plasma cell disorders are a spectrum of diseases ranging from monoclonal gammopathy of undetermined significance (MGUS), to smoldering multiple myeloma (SMM), to multiple myeloma (MM). Multiple myeloma is preceded by an asymptomatic precursor state in the majority of cases. While the vast majority of these patients do not progress to have symptomatic disease, there is an intermediate to high-risk subset of patients with SMM that do go on to meet criteria for MM, including hypercalcemia, anemia, renal insufficiency, and lytic bone lesions.

There are numerous risk stratification systems that have been devised to predict which patients have the highest risk of progression. The Mayo Clinic group identified 3 factors as predictors for early progression. these factors include a bone marrow plasma cell burden of greater than 20%, a monoclonal protein (M-spike) of 2g/dL or greater, and a ratio of involved to uninvolved serum free light chains of 20% or greater. Patients with one more of these risk factors have an increased risk of progression to MM in the first five years after diagnosis.

The current standard of care for the treatment of patients with SMM is observation because numerous early studies failed to demonstrate a survival advantage with pharmacologic intervention. More recent studies have aimed to select out the high-risk patients where intervention is more likely to be beneficial in preventing or delaying progression. The approaches have ranged in intensity and aim, with some approaches aimed at preventing or delaying progression, and others aimed at treating aggressively with curative intent. While the preliminary results of these studies have been promising, there is no consensus on the optimal approach in patients with intermediate to high-risk smoldering multiple myeloma.

Selinexor is a small-molecule selective inhibitor of nuclear export (SINE), which inhibits exportin-1 (XPO1) in a slowly reversible, covalent manner. XPO1 is a transport protein that is responsible for transport of over 200 proteins from the nucleus to the cytoplasm. Inhibition of XPO1 leads to accumulation of tumor suppressor proteins, cell-cycle regulators, and oncoprotein mRNAs in the nucleus and eventually leads to apoptosis of malignant cells. XPO1 inhibition has been shown to induce apoptosis in malignant MM cells and impede osteoclastogenesis without toxicity to surrounding bone marrow stromal cells (BMSCs).

Selinexor has been FDA approved for the treatment of relapsed and refractory multiple myeloma and is currently being studied in the frontline and relapsed settings with different therapeutic combinations in the STOMP trial. Selinexor has not been studied in the precursor disease population. While the exact mechanisms of progression from SMM to MM are incompletely understood, it has been shown that XPO1 expression is increased during progression of disease, which makes this a promising target in this population of patients. The investigators aim to limit the side effect profile while maintaining efficacy of treatment for SMM, with the goal of delaying or preventing progression to MM. The investigators hypothesize that at a low tumor-burden disease, a lower dose of selinexor may be efficacious and lead to an improved toxicity profile than standard dosing.

03

Conditions studied

  • Smoldering Multiple Myeloma

Keywords

  • Smoldering Multiple Myeloma
  • Smoldering Myeloma
  • Multiple Myeloma
  • Myeloma
  • MGUS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >/= 18 years
  • confirmed diagnosis of SMM according to the IMWG definition: serum M-protein >/= 3 g/dL or BMPC >10% but \<60%, or both.
  • Should not meet CRAB criteria: hypercalcemia, anemia, bone lesions, or renal insufficiency thought to be related to the plasma cell disorder.
  • Should have 1 of the following risk factors to be considered intermediate risk and 2 or more risk factors to be considered high-risk:
  • BMPC>/=20%
  • M-spike >/= 2g/dL
  • Involved to uninvolved sFLC ratio of >/= 20
  • normal hepatic function within 28 days prior to C1D1
  • Adequate renal function within 28 days prior to C1D1. Estimated (CrCl) calculated using formula of Cockcroft and Gault. CrCl >/= 15 mL/min.
  • Adequate hematopoietic function within 28 days prior to C1D1: (ANC)>/=1.5 x10\^9/L, >/=10g/dL, >/150x10\^9/L.
  • of >12 months.
  • PS 0-1
  • Subjects with must use 2 highly effective methods of effective or practice sexual abstinence throughout the study and continue for 6 months after the study has closed. Subjects who are surgically sterile (e.g., history of bilateral tubal ligation, hysterectomy, or whos partner is sterile are not required to use additional modes of contraception.
  • Ability to understand and willingness

Exclusion criteria

Exclusion Criteria:

  • Meets criteria for symptomatic MM as defined by any of the following, determined to be related to the plasma cell disorder

    • Hypercalcemia (corrected serum calcium >11.0 mg/dL)
    • Renal insufficiency (creatinine >2.0 mg/dL)
    • Anemia ( \<10g/dL)
    • One or more osteolytic bone lesions on radiography, but more than one lesion required if \<10% clonal bone marrow plasma cells. Based on MRI imaging, there must be more than one lesion >5mm in size.
    • Clonal bone marrow plasma cells ≥60%
    • An involved serum free light chain ≥ 100mg/L with the ratio of the involved/uninvolved free light chains also ≥100
  • Documented systemic light chain amyloidosis
  • Systemic >10mg prednisone (or equivalent) daily for other medical conditions.
  • Active invasive within the past 3 years that may affect the results or interfere with the interpretation of results of this study.
  • Non-invasive malignancy that was not treated with curative intent within the past 3 years that may affect the results or interfere with the interpretation of the results of this study.
  • Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 14 days of the receiving the first dose
  • Known active infection without adequate anti-retroviral therapy
  • Active gastrointestinal dysfunction that prevents patient from swallowing tablets or may interfere with absorption of study treatment
  • Pregnant, breast feeding, or planning to become pregnant within 6 months after the end of treatment.
  • Subject of that is not willing to use two methods of highly effective during treatment period and for 6 months after the end of treatment.
  • Any major medical or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results.
  • Prior exposure to a SINE compound, including Selinexor.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Experimental: Treatment

    Selinexor 40mg weekly for up to 12 cycles. Each cycle will be 28 days in length.

    Drug: Selinexor

Interventions

  • Low-dose Selinexor for the Treatment of Intermediate to High-Risk Smoldering Multiple Myeloma

06

What researchers measure

Primary outcomes

  1. Rate of progression to Multiple Myeloma

    The study will assess how long participants will not have the cancer get worse while treated with selinexor

    Time frame: 2 years after end of treament

Secondary outcomes

  1. Change in monoclonal protein (M-spike) or serum free light chains (sFLC)

    M-spike will be measured in g/dL and sFLC will be measured in mg/dL

    Time frame: 1 Year

  2. Progression free survival

    The study will assess how long participants will not have the cancer get worse while treated with Selinexor

    Time frame: 1 Year

  3. Rate of skeletal related events

    Time frame: 1 Year

  4. rate of adverse events

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Oct 2024, 14 months.

Of 26 phase 2 interventional studies under Smoldering Multiple Myeloma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 96. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2022
First posted
Oct 28, 2022
StartActual
Aug 21, 2023
Primary completionActual
Oct 29, 2024
CompletionEst.
Dec 31, 2025
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05597345
Responsible party
Brea Lipe (Professor - Department of Medicine , Hematology/Oncology (SMD), University of Rochester) — Principal investigator
First posted
Oct 28, 2022
Start date
Aug 21, 2023
Primary completion
Oct 29, 2024
Completion
Dec 31, 2025 (estimated)
Last update
Feb 10, 2025

Study contacts

Jodi Lipof
Contact
jodi_lipof@urmc.rochester.edu
6505042400
Jodi Lipof
principal investigator · University of Rochester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion